Stanley Chun-Wei Lee
Overview
Explore the profile of Stanley Chun-Wei Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
2285
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Z, Yoshimi A, Wang J, Cho H, Chun-Wei Lee S, Ki M, et al.
Cancer Discov
. 2020 Mar;
10(6):806-821.
PMID: 32188705
Although mutations in the gene encoding the RNA splicing factor SF3B1 are frequent in multiple cancers, their functional effects and therapeutic dependencies are poorly understood. Here, we characterize 98 tumors...
2.
Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, et al.
J Clin Invest
. 2019 Dec;
130(2):981-997.
PMID: 31855575
The protein-protein interaction between menin and mixed lineage leukemia 1 (MLL1) plays a critical role in acute leukemias with translocations of the MLL1 gene or with mutations in the nucleophosmin...
3.
Inoue D, Chew G, Liu B, Michel B, Pangallo J, DAvino A, et al.
Nature
. 2019 Oct;
574(7778):432-436.
PMID: 31597964
SF3B1 is the most commonly mutated RNA splicing factor in cancer, but the mechanisms by which SF3B1 mutations promote malignancy are poorly understood. Here we integrated pan-cancer splicing analyses with...
4.
Yoshimi A, Lin K, Wiseman D, Rahman M, Pastore A, Wang B, et al.
Nature
. 2019 Oct;
574(7777):273-277.
PMID: 31578525
Transcription and pre-mRNA splicing are key steps in the control of gene expression and mutations in genes regulating each of these processes are common in leukaemia. Despite the frequent overlap...
5.
Fong J, Pignata L, Goy P, Kawabata K, Chun-Wei Lee S, Koh C, et al.
Cancer Cell
. 2019 Aug;
36(2):194-209.e9.
PMID: 31408619
Cancer-associated mutations in genes encoding RNA splicing factors (SFs) commonly occur in leukemias, as well as in a variety of solid tumors, and confer dependence on wild-type splicing. These observations...
6.
Taylor J, Sendino M, Gorelick A, Pastore A, Chang M, Penson A, et al.
Cancer Discov
. 2019 Jul;
9(10):1452-1467.
PMID: 31285298
Altered expression of XPO1, the main nuclear export receptor in eukaryotic cells, has been observed in cancer, and XPO1 has been a focus of anticancer drug development. However, mechanistic evidence...
7.
Wang E, Lu S, Pastore A, Chen X, Imig J, Chun-Wei Lee S, et al.
Cancer Cell
. 2019 Feb;
35(3):369-384.e7.
PMID: 30799057
RNA-binding proteins (RBPs) are essential modulators of transcription and translation frequently dysregulated in cancer. We systematically interrogated RBP dependencies in human cancers using a comprehensive CRISPR/Cas9 domain-focused screen targeting RNA-binding...
8.
Chun-Wei Lee S, North K, Kim E, Jang E, Obeng E, Lu S, et al.
Cancer Cell
. 2018 Aug;
34(2):225-241.e8.
PMID: 30107174
Mutations affecting RNA splicing factors are the most common genetic alterations in myelodysplastic syndrome (MDS) patients and occur in a mutually exclusive manner. The basis for the mutual exclusivity of...
9.
Seiler M, Yoshimi A, Darman R, Chan B, Keaney G, Thomas M, et al.
Nat Med
. 2018 Feb;
24(4):497-504.
PMID: 29457796
Genomic analyses of cancer have identified recurrent point mutations in the RNA splicing factor-encoding genes SF3B1, U2AF1, and SRSF2 that confer an alteration of function. Cancer cells bearing these mutations...
10.
Yoshimi A, Balasis M, Vedder A, Feldman K, Ma Y, Zhang H, et al.
Blood
. 2017 Jun;
130(4):397-407.
PMID: 28576879
Chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) are myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap disorders characterized by monocytosis, myelodysplasia, and a characteristic hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF)....